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Cytokines are small secreted proteins that among many functions also play key roles in
the orchestration of inflammation in host defense and disease. Over the past years, a
large number of biologics have been developed to target cytokines in disease, amongst
which soluble receptor fusion proteins have shown some promise in pre-clinical studies.
We have previously shown proof-of-concept for the therapeutic targeting of interleukin
(IL)-33 in airway inflammation using a newly developed biologic, termed IL-33trap,
comprising the ectodomains of the cognate receptor ST2 and the co-receptor IL-1RAcP
fused into a single-chain recombinant fusion protein. Here we extend the biophysical
and biological characterization of IL-33trap variants, and show that IL-33trap is a stable
protein with a monomeric profile both at physiological temperatures and during liquid
storage at 4◦C. Reducing the N-glycan heterogeneity and complexity of IL-33trap
via GlycoDelete engineering neither affects its stability nor its inhibitory activity against
IL-33. We also report that IL-33trap specifically targets biologically active IL-33 splice
variants. Finally, we document the generation and antagonistic activity of a single-chain
IL-4/13trap, which inhibits both IL-4 and IL-13 signaling. Collectively, these results
illustrate that single-chain soluble receptor fusion proteins against IL-4, IL-13, and
IL-33 are novel biologics that might not only be of interest for research purposes and
further interrogation of the role of their target cytokines in physiology and disease, but
may also complement monoclonal antibodies for the treatment of allergic and other
inflammatory diseases.
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INTRODUCTION
Cytokines are small proteins secreted by immune cells that bind to specific high affinity
cell surface receptors. This subsequently initiates an intracellular signaling cascade, which
culminates in the activation of transcription factors to induce expression of specific genes
important for different cellular activities. Cytokines are considered key modulators in host
defense against external threats or injury, as well as in initiating and regulating both innate and
adaptive immunity. Dysregulated cytokine signaling leads to the development of inflammatory
and autoimmune diseases, as well as cancer. Several biologics preventing the activity of
cytokines have been developed as new protein-based therapeutics for inflammatory diseases.
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These include monoclonal antibodies neutralizing specific
cytokines or blocking their receptor, recombinant decoy
receptors targeting cytokines, as well as recombinant proteins
that can either be cytokine receptor agonists or antagonists (1).
Because of their versatility, efficacy and relative ease of large-
scale manufacturing, humanized monoclonal antibodies have
been the preferred treatment choice and several have emerged
as blockbuster drugs. For example, the anti-TNF antibody
Adalimumab reduces inflammation in a number of autoimmune
diseases including Crohn’s disease, ulcerative colitis, plaque
psoriasis, rheumatoid arthritis and ankylosing spondylitis (2,
3); Dupilumab is an anti-IL-4Rα monoclonal antibody used
to treat allergic diseases (4); and Mepolizumab blocks IL-
5 and ameliorates the symptoms of patients suffering from
severe eosinophilic asthma (5). On the other hand, recombinant
soluble receptor-based cytokine antagonists have also found
their way into the clinic. For instance, the dimeric soluble
TNFR2 receptor-based immunoglobulin (Ig) G1 Fc fusion
protein Etanercept is a blockbuster drug against ankylosing
spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid
arthritis (6). Similarly, Rilonacept is a dimeric fusion protein
consisting of the ligand-binding domains of the extracellular
portions of the human IL-1 receptor component (IL-1R1) and
IL-1 receptor accessory protein (IL-1RAcP) linked to an IgG1
Fc region, which is approved for clinical treatment of cryopyrin-
associated periodic syndromes (7, 8). Another cytokine receptor
based biologic is Aflibercept, which is a recombinant fusion
protein consisting of vascular endothelial growth factor (VEGF)-
binding portions from the extracellular domains of human
VEGF receptors 1 and 2, that are fused to a human IgG1 Fc
portion, and which is used for the treatment of age-related
macular degeneration (9). Finally, Anakinra is an example of
a recombinant form of the natural anti-inflammatory cytokine
IL-1 receptor antagonist (IL-1Ra) that competes with IL-1 for
binding to its receptor, and that was approved for the treatment
of rheumatoid arthritis as well as a number of autoinflammatory
diseases due to excess IL-1 (10). Despite these clinical successes,
existing biologics often only help a subset of patients or suffer
from other limitations such as side effects and resistance due to
the development of anti-drug antibodies, indicating the need for
new or complementary approaches.
IL-33, a member of the IL-1 family of cytokines, is best known
for its role in the activation of T helper (Th)2 cell-mediated (also
known as type 2) immunity at mucosal body surfaces, where it is
released from epithelial and endothelial cells exposed to allergens
and other cellular stress factors (11). IL-33 is also considered
to function as an “alarmin,” activating various immune cells (T
cells, macrophages, innate lymphoid cells type 2) upon binding
to its cell surface receptor ST2 [reviewed in Braun et al., (11)].
The pathological role of IL-33 is most firmly established in
the case of asthma, supported by a large body of experimental
data ranging from transgenic overexpression or local intra-
tracheal administration of recombinant IL-33, IL-33 or ST2 gene
ablations, and pharmacological inhibition of the IL-33 signaling
pathway in mice (11, 12). Consequently, IL-33-blocking agents
are actively developed as new therapeutic biologics. Such agents
include anti-IL-33 and anti-ST2 monoclonal antibodies as well as
recombinant decoy receptors corresponding to the extracellular
part of the IL-33 receptor ST2 (known as soluble ST2 or
sST2). For instance, Regeneron Pharmaceuticals, in collaboration
with Sanofi, entered Phase 2 clinical trials for asthma, chronic
obstructive pulmonary disease and atopic dermatitis with an anti-
IL-33 antibody (REGN3500). Another anti-IL-33 monoclonal
antibody, Etokimab (AnaptysBio), is also under evaluation or
completed Phase2a trials for moderate-to-severe adult atopic
dermatitis, chronic rhinosinusitis with nasal polyps, asthma and
peanut allergy (13). Moreover, two ST2-targeting monoclonal
antibodies, AMG282 (Genentech) and GSK3772847 (formerly
CNTO 7160; GlaxoSmithKline), are also in Phase2 clinical trials
for asthma.
IL-33 binds with relatively low affinity to its cognate cell
surface receptor ST2, which then serves as a binding platform to
recruit the co-receptor IL-1RAcP, thus forming a heterodimeric
high affinity signaling competent receptor complex (14). This
principle led us to engineer a recombinant fusion protein
(referred to as “IL-33trap”), comprising the extracellular domains
of ST2 (sST2) and IL-1RAcP (sIL-1RAcP) interconnected by a
flexible linker, which was anticipated to behave as a high affinity
single molecule antagonist of IL-33 cytokine activity. Indeed,
IL-33trap showed dramatically enhanced binding affinity to IL-
33 when compared to recombinant sST2, which corresponds
to the natural decoy receptor for IL-33. Moreover, IL-33trap
efficiently prevented the development of airway inflammation
and airway hyperreactivity in a murine asthma model (15).
More recently, IL-33trap was also shown to suppress colorectal
cancer tumor growth by decreasing infiltrating tumor-associated
macrophages that negatively impact tumor immunity (16). In
the present study, we focus on the further biophysical and
biological characterization of the IL-33trap. We also report the
generation and characterization of another single chain receptor
fusion-based cytokine modulator, termed IL-4/13trap, which
exhibits great capacity to inhibit IL-4 and IL-13. Altogether, our
data illustrate that single-chain soluble receptor fusion proteins
against IL-4, IL-13 and IL-33 are novel biologics that are not
only of interest as research tools, but may also complement
monoclonal antibodies for the treatment of allergic and other
inflammatory diseases.
MATERIALS AND METHODS
Expression Plasmids and Recombinant
Proteins
Plasmids have been deposited at the BCCM/GeneCorner plasmid
collection (www.genecorner.ugent.be) hosted by our department.
p4x-STAT6-Luc2P (LMBP09396), which contains a STAT6-
driven luciferase reporter gene, was purchased from Addgene.
pNFconluc, which contains an NF-κB–driven luciferase reporter
gene, was a gift from Dr. A. Israel (Institut Pasteur, Paris,
France), and pACTbgal (LMBP4341) was from Dr. J. Inoue
(Institute of Medical Sciences, Tokyo, Japan). Construction
of human and mouse IL-33traps, as well as production of
mouse IL-33trap in HEK 293 FreeStyle cells, were described
previously (15). Full length human IL-33 was PCR amplified
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from a human cDNA library and ligated into pCR-Blunt II-
TOPO. Splice variants were made by inverse PCR reaction.
Subsequently, IL-33 full length and splice variants with a C-
terminal 6xHis-tag were PCR amplified and cloned into pJExD
by homologous recombination (CloneEZ). The basic bacterial
expression vector pJExD, which allows crystal violet-induced
expression, was made by modifying the commercial vector pET-
Duet1 as follows: lacI and the first T7 promoter and lacO
binding site (Eco47III—BamHI) were replaced with a synthetic
sequence containing an eilR expression cassette and the crystal
violet inducible JExD promoter with eilR binding sites (17).
Expression of IL-33 splice variants in Escherichia coli BL21
was induced by addition of 100 nmol/L crystal violet (Sigma-
Aldrich, Belgium) for 3.5 h at 37◦C. Cells were collected by
centrifugation, lysed and soluble IL-33 variants were purified
using immobilized metal affinity chromatography using Ni-NTA
sepharose (IBA Lifesciences, Germany). Production of truncated
mouse IL-33 (residues 109–266) in Escherichia coli BL21 has
been described previously (15). Briefly, protein expression was
induced with 1 mmol/L isopropyl β-D-1-thiogalactopyranoside,
followed by overnight incubation at 28◦C. The bacterial pellet
was harvested by means of centrifugation, resolubilized, and
lysed by means of sonication. The lysate was centrifuged,
and soluble IL-33 was purified from the supernatant by using
immobilized metal affinity chromatography, followed by size
exclusion chromatography (SEC). Protein concentration was
determined with a bicinchoninic acid (BCA) protein assay kit.
The ectodomains of the human IL-13Rα1 and IL-4Rα were
PCR amplified from a human cDNA library and cloned into
pEF6-MycHisA to generate pEF-ShIL13Ra1 and pEF-ShIL4R,
respectively. To generate the IL-4/13trap expression plasmid,
a human IL-4Rα PCR fragment amplified from pEF-ShIL4R
and a linker sequence of 20 times repeating Gly-Gly-Ser (GGS)
triplets amplified from pCLG-Duba (LMBP6610) were cloned
into the pEF-ShIL13Ra1 vector via 3-way ligation. All constructs
were confirmed using DNA sequencing analysis. Human IL-
4/13trap and human IL-33trap were produced in HEK293T
cells and purified from the medium fraction by immobilized
metal affinity chromatography using Ni-NTA sepharose (IBA
Lifesciences, Germnay). To reduce the glycosylation complexity
and heterogeneity, murine IL-33trap was also produced in
suspension growth serum-free adapted HEK293 GlycoDelete
cells (18).
Cytokine Bioassays
HEK293T cells (gift from Dr. Hall, Department of Biochemistry,
University of Birmingham, United Kingdom) were seeded at 4
× 104 cells/well in 24-well plates and cultured in Dulbecco’s
modified Eagle medium supplemented with 10% FCS and
2 mmol/L L-glutamine. The next day, cells were transiently
transfected by calcium phosphate precipitation with specific IL-
33, IL-4, or IL-13 cytokine receptor expression plasmids. For
the IL-33 bioassay, cells were co-transfected with the NF-κB
reporter plasmid pNFconluc and the constitutively expressing
β-galactosidase plasmid pACTbgal. For the IL-4 and IL-13
bioassay, cells were co-transfected with STAT6 and the STAT6
reporter plasmid p4x-STAT6-Luc2P, as well as the constitutively
expressing β-galactosidase plasmid pACTbgal. 24 h later, cells
were stimulated with recombinant IL-33, IL-4, or IL-13 for
5 h. For cytokine neutralization experiments, cytokines were
incubated for 30min at room temperature with specific cytokine
trap inhibitors before addition to the cells. Cell lysates were
analyzed for luciferase activity and normalized based on β-
galactosidase levels to correct for potential differences in
transfection efficiency.
Measurement of Protein Aggregation via
SEC-MALLS
Potential protein aggregation was measured via size-exclusion
chromatography (SEC) coupled with multi-angle laser light
scattering (MALLS). Protein samples were injected onto a
Superdex 200 Increase10/300 GL column (GE Healthcare), with
PBS pH 7.4 as running buffer at 0.5 ml/min, coupled to an inline
ultraviolet-detector (Shimadzu), a multi-angle light scattering
miniDAWN TREOS instrument (Wyatt) and an Optilab T-
rEXrefractometer (Wyatt) at 25◦C. A refractive index increment
(dn/dc) value of 0.185 ml/g was used for protein concentration
and molecular mass determination. Data were analyzed using
the ASTRA6 software (Wyatt). Correction for band broadening
was applied using parameters derived from BSA injected under
identical running conditions. For the analysis of IL-33traps,
conjugate analysis was performed using theoretical protein
extinction coefficients and a dn/dc value of 0.160 ml/g for the
glycan modifier.
Measurement of Thermostability
Thermostability was measured by ThermoFluor R© assay as
described (19). Protein samples were diluted in a final
volume of 16 µl of PBS buffer and 1 µl of 300X SYPRO
Orange (InvitrogenTM, Thermo Fisher Scientific) was added.
Each experiment was run as a technical triplicate, with a
triplicate blank measurement without test protein. Fluorescence
in function of the temperature was recorded in a 348-well
LightCycler R© 480 (Roche Life Science) from 25 to 95◦C at
0.02◦C/s. Melting temperatures (Tm) were calculated as the V50
value of a Boltzmann sigmoidal curve fitted to the averaged
data points of the three replicates in each experiment. Onset
temperatures (To) were calculated as previously described (20).
For graphing, the raw data sets were averaged, blank corrected
and then normalized (minimal value at 0%, maximal value at
100%), using Prism 7 Software (GraphPad).
RESULTS
Use of a Flexible Linker Allows the
Generation of an Fc-Less Single-Chain
IL-33trap
Recombinant cytokine decoy receptor-based biologics such as
Etanercept, Rilonacept, and Aflibercept all contain the Fc portion
of human IgG1. Fusion to an Fc domain allows dimerisation of
the two receptor subunits and provides manufacturing, biological
and pharmacological advantages in vivo, including established
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large-scale affinity purification, half-life extension due to pH-
dependent binding to the neonatal Fc receptor (FcRn) (21). For
the construction of IL-33trap we used an alternative approach
that avoids the need for an Fc to induce receptor dimerisation.
More specifically, we cloned a flexible GGS linker sequence
between sST2 and sIL-1RAcP to ensure the intramolecular
formation of an active sST2/sIL-1RAcP heterodimeric receptor
complex (15). Although at that time we did not compare the
bioactivity of our linker containing IL-33trap with an IL-33trap
variant that does not contain a linker, it is likely that the linker is
needed for optimal domain orientation and heterodimerisation
between both receptor subunits and consequently the bioactivity
of IL-33trap. To further compare the effect of a linker sequence
with the effect of fusion to an Fc-moiety on IL-33trap bioactivity,
we generated recombinant human IL-33trap variants in which
both receptor subunits (sST2 and sIL-1RAcP) were either not
separated by a linker or contained a 7x or 12x GGS linker (shown
empirically to enable the formation of biologically active IL-
33trap), and compared these with the corresponding IL-33trap
constructs that also contain a human IgG1 Fc domain at the
C-terminus (Figure 1A).
The antagonistic activity of different human IL-33trap
constructs was analyzed by measuring their ability to inhibit IL-
33-induced activation of an NF-κB-dependent luciferase reporter
gene in HEK293T cells that were made IL-33 responsive by
transient transfection with human ST2. Prior to cell stimulation,
recombinant human IL-33 was incubated for 30min with
equimolar concentrations of each human IL-33trap variant
over a range of inhibitors/target ratios. An IL-33trap without
Fc and GGS linker had an almost 10-fold reduced activity
compared to a similar GGS-less construct fused to an Fc (IC50
of 748 pM and 90 pM, respectively; Figure 1B), suggesting that
the Fc-moiety allows the optimal IL-33trap conformation for
ligand binding, most likely by mediating dimerisation of two
IL-33trap molecules. Importantly, inclusion of a 7x GGS or
12xGGS linker sequence instead of an Fc also enhanced the
antagonistic effect of the IL-33trap (IC50 of 194 pM and 42 pM,
respectively; Figure 1C), with sIL-1RAcP-12xGGS-sST2 being
slightly more potent than sIL-1RAcP-sST2-Fc (IC50 of 42 vs.
90 pM; Figure 1C). Combined use of a 12xGGS linker and an
Fc fusion in a single IL-33trap construct (IC50 of 57 pM) did
not much further change the potency of a 12xGGS-only or Fc-
only construct (IC50 of 42 or 90 pM, respectively; Figures 1C,D).
However, additional Fc fusion leads to a more potent molecule
in the case of a shorter 7xGGS linker (IC50 67 vs. 194 pM;
Figures 1C,D). Collectively, these data illustrate that fusion of
either a GGS linker sequence or an Fc-moiety increases the IL-
33 antagonistic activity of an sIL-1RAcP-sST2 fusion protein
by enabling, respectively, intramolecular and intermolecular
interactions between sST2 and sIL-1RAcP that are necessary
for the formation of a high affinity IL-33 binding complex.
The lower potency of a 7xGGS containing construct (IC50 of
194 pM) compared to a 12xGGS (42 pM) construct suggests
that a longer linker increases molecular flexibility, favoring a
more optimal intramolecular interaction between sST2 and sIL-
1RAcP. Importantly, our data illustrate that insertion of a flexible
12xGGS linker between both IL-33 receptor subunits allows
the formation of a single-chain fusion protein with high IL-33
antagonistic activity, circumventing the need for Fc fusion and
Fc-mediated dimerisation.
IL-33trap Is Biophysically Stable During
Liquid Storage and at Physiological
Temperature
The biophysical behavior of therapeutic proteins is very
important for the correct development and optimisation of
biologics, since it may impact many aspects of drug function,
stability and activity. Excessive aggregates and fragmentation, as
well as denaturation or oxidation are indicative of an unstable
product, unsuitable for in vivo use. For this reason, we sought
to characterize the molecular and thermal stability of the murine
20xGGS-linker containing but Fc-less IL-33trap for which we
previously showed an inhibitory effect upon local delivery in a
mouse asthma model (15). First, we examined whether IL-33trap
is prone to form aggregates during storage. IL-33trap was stored
frozen in PBS at −80◦C or liquid-stored at 4◦C for a time period
of 10 days. To determine the presence of potential aggregates,
we used size-exclusion chromatography (SEC) coupled with
ultraviolet (UV), multi-angle light scattering laser (MALLS) and
refractive index (RI) detectors. Protein elution fractions were
identified as eluting species with a peak in both UV absorbance
and differential RI (dRI) intensity. IL-33trap, either frozen-
stored at −80◦C or liquid-stored at 4◦C for 10 days, was found
to be highly homogeneous, adopting monodisperse assemblies,
with a protein molecular mass comparable to the theoretical
(Figure 2A).
We next assessed the thermostability of IL-33trap using
ThermoFluor R© assay (19), and melting temperature (Tm) was
calculated as the V50 value of a Boltzmann sigmoidal curve
fitted to the melting curve (19, 22). The analysis showed a Tm
and a To of 55 and 46.5
◦C, respectively which is well above the
physiological temperature of 37◦C (Figure 2B). Together, our
data indicate that IL-33trap is a stable molecule at physiological
temperature and does not form aggregates when liquid-stored at
4◦C for up to 10 days.
Glycosylation Does Not Affect IL-33trap
Bioactivity
We previously showed that mouse IL-33trap expressed in
HEK293T cells is glycosylated (15). To further estimate the
degree of glycosylation, we calculated the total protein and
glycan molecular weight on IL-33trap using SEC-MALLS and
ASTRA6 software (Wyatt), showing that IL-33trap is heavily
glycosylated (25–35% of total mass) (Figure 2A). Using NetNglyc
1.0 Server and NetOglyc 4.0 Server prediction (23), 15 potential
N-glycosylation and 1–4 potential O-glycosylation sites were
found. Although not all of these sites are likely to be occupied,
the high number of glycosylation sites leads to significant product
heterogeneity, which is further complicated by the inherent
difference in glycan chain length and complexity in eukaryotic
expression systems. This is a major challenge for efficient
purification at high yield, to set sound specifications for product
release and hence to assure batch reproducibility. It is also
Frontiers in Immunology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 1422
Holgado et al. Soluble Receptor-Based Cytokine Inhibitors
FIGURE 1 | Comparison of the effect of Fc fusion and introduction of a 12xGGS linker on the inhibitory capacity of human IL-33trap. (A) Schematic representation of
human IL-33trap constructs (numbers indicate the amino acid boundaries of the receptor ectodomains). (B–D) Effect of different fusion proteins on IL-33 induced
NF-κB activation. HEK293T cells were treated with recombinant human IL-33 that was pre-incubated with equimolar concentrations of the indicated fusion proteins
over a range of inhibitors/target ratios and assayed for NF-κB activity as described in Material and Methods. Values represent means ± SE of technical triplicates.
Results are representative of at least two independent experiments.
likely to attribute significant heterogeneity in pharmacokinetic
behavior of the molecule, due to differential lectin-mediated
blood clearance of different glycoforms. Therefore, we decided to
reduce the glycosylation complexity and heterogeneity of mouse
IL-33trap using HEK293 GlycoDelete technology (18), which
reduces glycosylation to short single-branch oligosaccharides
that are partially sialylated. Indeed, IL-33trap produced in
HEK293 GlycoDelete is notably less glycosylated (6% of the total
mass) compared to the original IL-33trap molecule produced in
HEK293 FreeStyle cells (25–35% of the total mass) (Figure 2A).
We then compared the thermostability and antagonistic activity
of the glycosylated and under-glycosylated IL-33trap variants.
Reduced glycosylation had only a mild effect on the melting
temperature (Figure 2B), and did not affect the ability of IL-
33trap to inhibit IL-33-induced NF-κB activation (Figure 2C).
IL-33trap Specifically Targets Active IL-33
Splice Variants
Human IL-33 mRNA can be alternatively spliced in several
smaller IL-33 splice variants lacking exon 3, 4, 5 or a combination
thereof, which are expressed in different cell types in different
proportions (24). In contrast to deletion of exons 3 and 4,
absence of exon 5 results in loss of IL-33 activity (25), which is
consistent with the fact that exon 5 encodes amino acid residues
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FIGURE 2 | Glycosylated and under-glycosylated murine IL-33trap do not form aggregates and are biophysically stable during liquid storage and at physiological
temperature. (A) SEC-MALLS analysis of murine 20xGGS linker-containing IL-33trap expressed in HEK293T or HEK293 GlycoDelete cells (referred as IL-33trapGD)
and frozen-stored vs. liquid-stored at 4◦C for a time period of 10 days. SEC elution profiles of IL-33trap (full line) and IL-33trapGD (dashed line) are plotted as the
normalized differential refractive index (dRI, left vertical axis) as a function of the elution volume (mL). Molecular weight of IL-33trap and IL-33trapGD as determined by
MALLS (kDa, right vertical axis) is dissected by protein conjugate analysis in total (red), protein (blue) and sugar (green) mass and is reported as the number-average
molar mass across the elution peak ± SD. Only the total mass (red) of IL-33trapGD is reported as protein conjugate analysis did not yield significant glycan mass. n =
1 sample injected. SEC-MALLS data was analyzed using ASTRA6 software (Wyatt) and graphs were plotted using GraphPad Prism software. (B) Melting curves of
murine IL-33trap and IL-33trapGD plotted as normalized fluorescence intensity in function of increasing temperature, determined by ThermoFluor® assay. Values of
melting temperature (Tm) and onset temperature (To) were calculated using GraphPad Prism software. (C) Comparison of the effect of IL-33trap and IL-33trapGD on
IL-33 induced NF-κB activation. HEK293T cells were treated with recombinant murine IL-33 that was pre-incubated with murine IL-33trap or IL-33trapGD and
assayed for NF-κB activity as described in Material and Methods. Values represent means ± SE of technical triplicates. Results are representative of at least two
independent experiments.
that are critical for ST2 binding (26). Importantly, binding of
inactive IL-33 isoforms to IL-33-neutralizing biologics would
serve as a natural sink and decrease drug availability. However,
because IL-33trap is a receptor-based biologic, it is expected
to exclusively interact with bioactive receptor-binding IL-33
isoforms and to be insensitive to the presence of inactive IL-
33 splice variants. To further test this hypothesis, we generated
IL-33 splice variants lacking exons 3 and 4 (IL-331e3-4) or
exons 3, 4 and 5 (IL-331e3-5) (Figure 3A), and analyzed
their activity in an IL-33 bioassay. As shown previously, IL-
331e3-4 efficiently induced NF-κB activation, while IL-331e3-
5 was inactive (Figure 3B). Furthermore, NF-κB activation
induced by IL-331e3-4 was efficiently inhibited by IL-33trap
(Figure 3C). We next performed a competition assay, where we
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pre-incubated mature IL-33 with IL-33trap in the presence of
increasing concentrations of either IL-331e3-4 or IL-331e3-
5 splice variants. Consistent with its receptor-binding capacity,
addition of IL-331e3-4 reduced the ability of IL-33trap to inhibit
IL-33 signaling, while addition of IL-331e3-5 had no effect
(Figure 3D). These results illustrate that inactive IL-33 splice
variants will not act as a sink for IL-33trap, which might offer a
significant advantage compared to certainmonoclonal antibodies
that, depending on the recognized epitope, might not always
distinguish between active and inactive IL-33 isoforms.
Generation and Validation of a Human
IL-4/13 Trap as a Dual Cytokine Antagonist
As for the IL-33trap, a similar approach using single-chain
soluble receptor fusion proteins can be used to target other
cytokines that signal through a heterodimeric receptor complex.
In this regard, we have previously reported the design and
validation of TSLP-trap, a fusion protein which consists of
the extracellular domains of TSLPR and IL-7Rα fused via a
20xGGS flexible linker (27). Together with IL-33 and IL-25,
the epithelium-derived cytokine TSLP is considered a central
orchestrator of Th2 responses in atopic disorders, and therefore
a promising therapeutic target. Similarly, IL-4 and IL-13 are
in the spotlight as interesting dual therapeutic targets in type
2-driven inflammatory disease (28). Importantly, these two
cytokines both bind to the type II receptor consisting of IL-
4 receptor alpha (IL-4Rα) and IL-13Rα1 (29) (Figure 4A),
offering a possibility to simultaneously target two cytokines
with one inhibitor. Using a similar design as IL-33trap (15), we
generated and validated a new human IL-4/13trap, consisting
of the extracellular domain of human IL-13Rα1 fused to the
extracellular domain of human IL-4Rα via a flexible 20xGGS
linker. The expression construct also contains the human IL-
13Rα1 signal sequence at the N-terminus, which allows protein
secretion, and a myc/His tag at the C-terminus to facilitate
protein purification and detection (Figure 4A). Human IL-
4/13trap was produced using HEK293 FreeStyle cells to ensure
proper folding, and purified from conditioned media using
immobilized metal affinity chromatography and size exclusion
chromatography, as described in materials and methods.
To test whether IL-4/13trap displays antagonistic properties,
we investigated its ability to inhibit both IL-4 and IL-13
signaling in a cell-based assay. To this end, HEK293T cells
were made responsive to either IL-4 or IL-13 by transfection
with human IL-4Rα and IL-13Rα1, and downstream STAT6
activation was followed via STAT6-dependent luciferase reporter
gene expression. IL-4 as well as IL-13 treatment resulted in robust
STAT6 activation (Figure 4B). Importantly, pre-incubation of
either IL-4 or IL-13 with equimolar concentration of IL-4/13trap
strongly reduced IL-4- and IL-13-induced STAT6-dependent
luciferase activity (IC50 of 465 pM and 434 pM, respectively)
(Figure 4B). These data convincingly demonstrate that IL-
4/13trap behaves as a strong IL-4 and IL-13 antagonist and
illustrate the feasibility to develop recombinant single-chain
soluble receptor fusion proteins as novel biologics for the
inhibition of a wide range of cytokines or other protein ligands
that signal via a heterodimeric receptor complex.
DISCUSSION
Because of the important role of cytokines in human
autoimmune and inflammatory diseases, many biologics
targeting cytokines and their receptors have been developed over
the past years. Several soluble receptor-based biologics, such as
the TNF antagonist Etanercept, the IL-1 antagonist Rilonacept,
and the VEGF antagonist Aflibercept, are already actively used
in the clinic as alternatives for monoclonal antibodies. In all
cases, soluble receptors were engineered to encode an IgG Fc
region to increase half-life and to permit dimerisation and high
affinity ligand binding. A similar approach has been described
for IL-4 and IL-6 neutralizing trap molecules (30), which
have not yet entered the clinic. The use of Fc fusion to enable
dimerisation doubles the size of the inhibitor (> 250 kDa in
the case of Rilonacept, glycosylation not included), limiting its
tissue permeability, which may be even more critical in certain
conditions such as asthma where mucus imposes an additional
barrier. Moreover, larger proteins typically result in lower
expression levels while higher dosing is needed compared to
smaller proteins (∼90 kDa in the case of IL-33trap) to achieve the
same molar concentration. The presence of an Fc portion could
also lead to side effects due to nonspecific binding to Fc receptors
or Fc-associated effector functions, although Fc engineering
can also overcome such problems. However, it remained
unclear whether Fc-fusion-driven bivalency also contributes
to the cytokine neutralizing activity of soluble receptor fusion
proteins like the IL-33trap. We have demonstrated here that
the Fc moiety strongly enhances the inhibitory capacity of a
linker-less IL-33trap molecule, indicating a role for Fc-mediated
dimerisation in the formation of a fully functional soluble
receptor complex. The need for Fc-mediated dimerisation
could however be completely replaced by the introduction of
a flexible linker (12xGGS) between both receptor subunits,
which allowed the formation of a single-chain fusion protein
with an optimal conformation for high affinity ligand binding.
The use of a flexible linker in the design of IL-33trap thus
offers a significantly different candidate biotherapeutic as an
alternative to Fc fusion. The use of Fc-less fusion biologics
could be especially relevant for maximizing exposure of the
therapeutic in certain tissues like the eye and lung upon local
delivery, where FcRn-mediated transcytosis of Fc-fusion proteins
across epithelial and endothelial cells would otherwise mediate
transport into systemic circulation.
The manufacturability of therapeutic proteins entails major
challenges to ensure drug efficacy and safety. Therefore,
appropriate molecular characterization and optimisation of these
biologics is crucial to ensure protein stability, homogeneity, low
immunogenicity as well as optimal pharmacokinetic properties.
Therapeutic proteins are often susceptible to thermal stress,
which can cause drastic conformational changes resulting
in reduced drug efficacy and stability. Furthermore, protein
unfolding in vivo may favor intermolecular protein interactions
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FIGURE 3 | Human IL-33trap specifically targets active IL-33 splice variants (A) Schematic representation of human IL-33 splice variants and encoded protein
isoforms. (B) NF-κB activation induced by different IL-33 splice variants. (C) Effect of IL-33trap on NF-κB activation induced by different IL-33 splice variants. (D)
Effect of the presence of IL-33 splice variants on the ability of IL-33trap to inhibit IL-33 induced NF-κB activation. NF-κB activity was measured in HEK293T cells as
described in Material and Methods. Values represent means ± SE of technical triplicates. Results are representative of at least two independent experiments.
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FIGURE 4 | Human IL-4/13trap inhibits IL-4 and IL-13 activity. (A) Schematic representation of the type II receptor complex for IL-4 and IL-13 (also receptor
phosphorylation and recruitment of STAT6 is shown), and the corresponding human IL-4/13trap construct (numbers indicate the amino acid boundaries of the
receptor ectodomains). (B) Effect of human IL-4/13trap on IL-4- and IL-13-induced STAT6 activation. HEK293T cells were treated with recombinant human IL-4 or
IL-13 that was pre-incubated with human IL-4/13trap and assayed for STAT6 activity as described in Material and Methods. Values represent means ± SE of technical
triplicates. Results are representative of at least two independent experiments.
and subsequent aggregates formation, which in turn could
trigger immune responses inducing formation of anti-drug
antibodies (31, 32). SEC-MALLS analysis indicated that IL-33trap
does neither form aggregates nor undergo denaturation above
physiological temperatures. Moreover, IL-33trap stability was
not affected during liquid storage, which may be of interest for
clinical practices as it might facilitate patient self-administration.
The quality of protein-based biologics may also be determined by
protein glycosylation. Inherent differences in glycan chain length
and complexity in eukaryotic expression systems can result in
highly heterogeneous and complex glycosylation pattern (33).
This is a major challenge to ensure efficient purification at high
yield and batch reproducibility. Our data show that reducing
glycosylation complexity and heterogeneity of IL-33trap using
HEK293 GlycoDelete technology does not affect its bioactivity.
The complexity of cytokine networks is drastically increased
by the generation of multiple cytokine and cytokine receptor
isoforms due to alternative splicing, differential promotor usage,
or posttranslational modifications such as proteolytic cleavage
and degradation (34, 35). This increases the risk that certain
active isoforms or variants may escape recognition by epitope-
specific monoclonal antibodies, leading to drug resistance.
Unfortunately, the specific epitopes that are recognized by
monoclonal antibodies that are in clinical development have not
been reported in literature. Alternatively, inactive isoforms that
do bind monoclonal antibodies may act as a sink, again reducing
that efficacy of the biologic. Also in the case of IL-33, alternative
splicing (24) and proteolytic cleavage (34) have been described,
creating tens of active and inactive IL-33 isoforms. Possibly, some
of these variants may escape or interfere with currently used IL-
33 neutralizing monoclonal antibodies, which may lead to poor
responses in preclinical or clinical studies. Importantly, as the
here described soluble receptor-based cytokine traps fully mimic
cytokine-binding by endogenous cell surface receptors, they are
expected to neutralize all biologically active cytokine isoforms
and be insensitive to the presence of inactive isoforms, as also
documented in the present study in the case of specific IL-33
splice variants.
Although targeting of specific cytokines with receptor-based
fusion proteins and monoclonal antibodies have demonstrated
beneficial clinical outcomes in patients suffering from a wide
variety of inflammatory disorders (1), functional redundancy of
cytokines as well as the development of anti-drug antibodies
often limits the success of specific cytokine therapies. Thus,
combinatorial treatment approaches simultaneously targeting
several cytokines may improve clinical outcomes, which has also
been documented for IL-33 and TSLP in preclinical studies (36).
Therefore, combination of IL-33trap with TSLPtrap, which we
have previously described as a 20–30 fold more potent TSLP
inhibitor in vitro than the anti-TSLP antibody Tezepelumab (27),
might be an interesting therapeutic approach. Dual targeting
of IL-4 and IL-13 with Dupilumab, a monoclonal antibody
targeting IL-4Rα, has recently entered the clinic for certain
allergic diseases (37, 38). Likewise, a novel bispecific llama-based
antibody simultaneously targeting IL-4Rα and IL-5, providing
a triple blockade of IL-4, IL-13 and IL-5 signaling, has been
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developed (39). Of interest, simultaneous inhibition of IL-13 and
IL-33 signaling was shown to inhibit allergic airway inflammation
in mice more effectively than inhibition of either cytokine alone
(40). In the present study we have shown that our design of
single-chain soluble receptor fusion proteins for the development
of cytokine traps is not only applicable to IL-33 and TSLP, but also
to IL-4 and IL-13. It will therefore be of interest to further test
the effect of the here described IL-4/13trap in preclinical mouse
models. Also, the generation of multi-specific cytokine trap
therapeutics, by fusing different cytokine trap proteins, might be
a path worth to consider. So far, only murine IL-33trap has been
tested in vivo in a mouse asthma model (15). It will be interesting
to also develop clinically relevant in vivo models where the
human IL-33 trap can be tested. In preliminary experiments
we have observed that repetitive intratracheal administration of
human IL-33 in mice induces lung eosinophilia, which can be
prevented by treatment of mice with human IL-33trap. Use of
humanized mice reconstituted with human immune cells (41),
which are then intratracheally injected with human IL-33, might
also be an option. Ideally, one might use humanized mice in
which the murine IL-33 gene has been replaced by the human
IL-33 gene, which would allow to test the effect of human IL-
33trap in an allergic disease mouse model that relies on human
IL-33 production from epithelial or endothelial cells. However,
it remains to be seen if such a human IL-33 transgene will
be regulated similarly to the mouse gene in a murine context.
Similar approaches might be applicable for preclinical studies
using IL-4/13trap.
In conclusion, following the quest for additional novel
anti-cytokine biologics, our data illustrate the potential of
recombinant single-chain soluble receptor fusion proteins as
novel anti-cytokine biologics. Cytokine traps targeting IL-33,
TSLP, IL-4 and IL-13 are novel tools that nicely complement
the use of monoclonal antibodies for the treatment of allergic
diseases. Moreover, the translational impact of such therapeutics
can be expected to be much broader than allergic diseases.
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